Four Week, Double Blind, Placebo Controlled Phase III Trial Evaluating The Efficacy, Safety And Pharmacokinetics Of Flexible Doses Of Oral Ziprasidone In Children And Adolescents With Bipolar I Disorder (Manic Or Mixed).
Withdrawn prior to enrolment
Phase of Trial: Phase III
Latest Information Update: 29 Apr 2015
At a glance
- Drugs Ziprasidone (Primary)
- Indications Bipolar I disorders
- Focus Therapeutic Use
- Sponsors Pfizer
- 22 Jun 2010 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 08 May 2010 New trial record